About Neurocrine
Neurocrine is a publicly listed company based in San Diego (United States) founded in 1992, and was acquired by Immedica in January 2026. Neurocrine has raised $10 million across 4 funding rounds from investors including BB Biotech, Immedica and MQS Management. The company has 1,800 employees. Neurocrine has completed 2 acquisitions, including Neurocrine UK and Soleno Life. Its chief executive, as recorded, is Kevin Gorman. Its website neurocrine.com draws about 39 thousand monthly visits. Neurocrine offers products and services including Medicines and Clinical Studies. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Endocrine disorders. Its legal entity is Neurocrine Biosciences, Inc. Its competitors include Biogen, PTC Therapeutics and Biohaven Pharmaceutical; 3 of its 3 listed competitors have raised funding.
Company details
Developer of small molecule therapeutics for endocrine and CNS disorders. The companys product line include elagolix, a gonadotropin-releasing hormone antagonist for endometriosis and uterine leiomyoma, and NBI-98854 a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.
- Headquarters San Diego, United States
- Employees 1,800
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website neurocrine.com
- Social LinkedIn Facebook
- Acquired by Immedica (Jan 2026)
- Legal Name Neurocrine Biosciences, Inc.
- Annual Revenue$2.86 B (USD)21.45as on Dec 31, 2025
- Net Profit$478.6 M (USD)40.23as on Dec 31, 2025
- EBITDA$666.6 M (USD)6.81as on Dec 31, 2025
- Total Equity Funding$10M (USD)
in 4 rounds
- InvestorsBB Biotech
& 3 more
- Employee Count1,800
- Investments & AcquisitionsNeurocrine UK
& 1 more
- Acquired byImmedica
(Jan 2026)
Products & Services of Neurocrine
Neurocrine offers a comprehensive portfolio of products and services, including Medicines and Clinical Studies.
Treatments for neurological and neuropsychiatric disorders
Investigations into potential treatments for rare diseases
Funding Insights of Neurocrine
Neurocrine has successfully raised a total of $10M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10M
- Total Rounds 4
- First Round $10M
(Dec 2009)
- Investors Count 3
All 4 funding rounds of Neurocrine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | Post-IPO | – | – | ||
| Mar 2019 | Post-IPO | – | – | ||
| Apr 2017 | $518M | Post-IPO | – | – | – |
| Dec 2009 | $10M | Private Equity Round | – | – |
4 investors in total: 4 institutional.
Investors in Neurocrine
Neurocrine has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include BB Biotech, Immedica and MQS Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in Asia and Europe | 1993 | bbbiotech.ch | Schaffhausen, Switzerland | |
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Offers fundamentally driven quantitative global macro investment strategies as a registered adviser. | 2008 | mqsmanagement.com | New York, United States | |
Therapeutic agents for oncology, neurology, and related diseases are developed. | 2017 | immedica.com | Stockholm, Sweden |
Investor details for Neurocrine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neurocrine
518 people are tracked at Neurocrine (146 in leadership, 8 in board & advisors, 364 in team); the tracked headcount is 1,800.
| Name | Role | Group |
|---|---|---|
Kevin Gorman | CEO | Leadership |
David W. Boyer | Chief Corporate Affairs Officer | Leadership |
Rye Dalton | VP Commercial Analytics And Operations | Leadership |
Dr. Mandakini Goel | Associate Director, Commercial Analytics | Leadership |
Denise Valentino | Sr. Director Global Trade Compliance & Logistics | Leadership |
Jonathan Terry | Director, Patient Access - East US Zone | Leadership |
Isabelle Brayman | Assoc. LTC & Data Operations Director | Leadership |
Dimitri E. Grigoriadis | Chief Research Officer | Leadership |
Liz Reynolds | Director, Corporate Communications | Leadership |
Jude Onyia | Chief Scientific Officer | Leadership |
Chad Paavola | Executive Scientific Director, Biologics Lead Optimization | Leadership |
Suzanne Robinson | Associate Director, Patient Engagemet & Advocacy | Leadership |
Chelsey Roberts | Associate Director, Patient Support Services | Leadership |
Ingrid Delaet | Chief Regulatory Officer | Leadership |
Kyle W. Gano | CEO | Leadership |
Dan Ramirez | Director, Commercial Insights, Analytics, And Competitive Intelligence | Leadership |
Dr. Guy Meno-Tetang | Senior Scientific Director, Clinical Pharmacology | Leadership |
Shane McCarrey | Sr. Human Resources Director | Leadership |
Tony Jewell | Executive Director Of Communications | Leadership |
Richard A. Moore Jr. | Executive Director & Head, Product Development | Leadership |
498 more people are available in the full profile.
Complete people profiles for Neurocrine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Neurocrine
Neurocrine is a publicly listed company on the NASDAQ with ticker symbol NBIX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Feb 2000
- Listed onFRA: NB3
- Listed entityNeurocrine Biosciences, Inc.
- Exchange sectorHealth technology
- ISINUS64125C1099
- Share price$135.13 (-4.41% on the day) · 2026-10-13
- Market capitalisation$13.74B
- Price to earnings19.8
- EPS (diluted, trailing year)$6.83
- Volume (last session)1,568,446
Financials of Neurocrine
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.86B | $478.6M | $666.6M |
| 2024 | $2.36B | $341.3M | $624.1M |
| 2023 | $1.89B | $249.7M | $416.1M |
| 2022 | $1.49B | $154.5M | $266.3M |
| 2021 | $1.13B | $89.6M | $218.7M |
Detailed financial statements for Neurocrine
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neurocrine
Neurocrine has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Neurocrine UK and Soleno Life.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule therapeutics for Prader-Willi Syndrome hyperphagia are developed. | soleno.life | Redwood, United States | 1999 | Apr 2026 | •••• | |
Hormone therapeutics for rare and chronic endocrine diseases are developed. | diurnal.com | Cardiff, United Kingdom | 2004 | Aug 2022 | $56.12M |
Complete acquisition details for Neurocrine
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Neurocrine
7 dated milestones of Neurocrine across 34 years, from founding to its latest funding, stage changes and deals.
- Founded Neurocrine is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $10.0M.
- Acquisition Acquires Neurocrine UK.
- Funding Latest funding round, Post-IPO,.
- Exit Acquired by Immedica.
- Acquisition Acquires Soleno Life.
Competitors of Neurocrine
Neurocrine has 3 listed competitors in our database, 3 of them funded. They include Biogen, PTC Therapeutics and Biohaven Pharmaceutical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. |
Detailed competitors of Neurocrine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Neurocrine
The website of Neurocrine (neurocrine.com) receives about 39.1K visits a month and ranks #927,855 among all websites worldwide, #1,119 in Biotechnology and Pharmaceuticals.
- Monthly visits39.1K
▲ 18.8% vs previous month
- Unique visitors17.6K
per month
- Global rank#927,855
among all websites
- Category rank#1,119
Health · Biotechnology and Pharmaceuticals
- Bounce rate48%
- Pages per visit1.8
- Average visit35 sec
- DevicesDesktop 58% · Mobile 42%
Websites whose visitors overlap most with Neurocrine. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
califesciences.org | califesciences.org | 100% | #1,611,022 | – | |
| siga.com | 95% | 8.4K | #3,215,987 | View details | |
| genoptix.com | 95% | View details | |||
| bio-quant.com | 95% | View details | |||
| cambrex.com | 95% | 35K | #883,665 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for Neurocrine
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Neurocrine (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neurocrine
Complete news archive for Neurocrine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neurocrine
Neurocrine was founded in 1992 and raised its 1st funding round 17 years after it was founded.
Neurocrine is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Kevin Gorman is the CEO of Neurocrine, as recorded in our data.
Neurocrine is a funded company, having raised a total of $10M across 4 funding rounds to date. The company's 1st funding round was a Private Equity Round of $10M, raised on Dec 2009.
Neurocrine has 1,800 employees.
Annual revenue of Neurocrine is $2.86B as on Dec 31, 2025.
Developer of small molecule therapeutics for endocrine and CNS disorders. The companys product line include elagolix, a gonadotropin-releasing hormone antagonist for endometriosis and uterine leiomyoma, and NBI-98854 a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.
Neurocrine's top competitors include PTC Therapeutics, Biohaven Pharmaceutical and Biogen.
Neurocrine offers Medicines and Clinical Studies.
Yes, Neurocrine is publicly traded on NASDAQ under the ticker symbol NBIX.
Neurocrine has made 2 acquisitions, including Neurocrine UK, and Soleno Life.
Neurocrine has 4 investors. Key investors include BB Biotech, Immedica, MQS Management, and Venrock.